Cullinan Q1 net loss $48.5M; CLN-978 gains EMA approval for RA, expands into Sjögren's

Cullinan Therapeutics, Inc.

Net loss of $48.5M in Q1 2025 vs $37.1M in Q1 2024; R&D expenses rose to $41.5M.
Cash and investments $567.4M as of March 31, 2025; runway into 2028 reaffirmed.
EMA approved Phase 1 study of CLN-978 in active, difficult-to-treat rheumatoid arthritis; to start Q2 2025.
CLN-978 Phase 1 in Sjögren's disease to initiate in U.S. in Q2 2025; SLE data expected Q4 2025.
CLN-619 discontinued in gynecological cancers; zipalertinib REZILIENT1 results at ASCO June 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.